Quantum-Si regains Nasdaq compliance, and Quantum-Si stock stays listed

Published on 10/16/2026 at 01:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

QSI reported USD 344,000 in second-quarter revenue, down 41.80 percent year over year. Proteus launch timing now anchors Quantum-Si stock in 2027.

Listing status and operating milestones

Nasdaq closed Quantum-Si's compliance matter on October 15, 2026 after 10 sessions above the USD 1.00 threshold.
Second-quarter revenue was USD 344,000, down 41.80 percent from the prior-year quarter.
Quantum-Si is scheduled to report third-quarter 2026 results on November 11, 2026.

QSI, US74765K1051, Illustration mit AI erstellt.

Quantum-Si (ISIN US74765K1051) regained Nasdaq compliance after its closing bid price stayed at or above USD 1.00 for 10 consecutive business days. The company announced the resolution on October 15, 2026, in a release distributed by GlobeNewswire.

Compliance removes a listing hurdle

Nasdaq told Quantum-Si that the matter was closed after the Class A common stock met Listing Rule 5450(a)(1). The announcement removes the immediate delisting issue, but the USD 1.00 threshold remains a concrete condition for continued listing.

The sequence also shows why the latest notice matters. On July 23, 2026, Quantum-Si had been notified that its stock closed below USD 1.00 for 30 consecutive business days, according to TipRanks. On October 8, 2026, the company reported detection of 19 amino acids in its Proteus development program, as reported by Investing.com. On October 15, 2026, Nasdaq confirmed compliance after 10 sessions above the threshold.

What does the development path mean?

The operating data remain demanding. Quantum-Si generated USD 344,000 of revenue in the second quarter of 2026, versus USD 591,000 in the second quarter of 2025, a decline of 41.80 percent. The figures and the Proteus timetable were discussed in the second-quarter call carried by Yahoo Finance.

Management moved the planned Proteus commercial launch to the second quarter of 2027 and said the system should launch with detection of 19 or 20 amino acids. That development schedule now sits alongside the listing milestone, so product execution and financial discipline remain closely connected.

Two dates shape the next phase

MarketWatch lists November 11, 2026, for Quantum-Si's third-quarter 2026 results and March 8, 2027, for its 2026 earnings report. Those dates provide the next scheduled checkpoints for revenue, cash use and Proteus execution.

Market value remains below the yearly high

Quantum-Si had a market capitalization of USD 260.6 million as of October 15, 2026. Its 52-week range was USD 0.69 to USD 3.10 on the same date, leaving the compliance milestone as a company-specific event rather than a valuation conclusion.